Shanghai Fosun Pharmaceutical (Group) Co. has signed a definitive agreement to acquire 86% of India's Gland Pharma, a pure-play generic injectable pharmaceutical products firm backed by global private equity giant KKR, for US$1.26 billion. Fosun Pharma will purchase all shares owned by a unit of KKR, in addition to shares purchased from other shareholders of […]
Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.
Visit the original source and full text: China Money Network
Any news and links syndicated from other sources are copyright those respective websites and/or publications. We post brief synopsis and links per what the respective websites' RSS feeds provide.